Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.607
-0.042 (-6.53%)
At close: Feb 21, 2025, 4:00 PM
0.610
+0.003 (0.43%)
After-hours: Feb 21, 2025, 7:06 PM EST
Elevation Oncology Employees
Elevation Oncology had 29 employees as of December 31, 2023. The number of employees decreased by 4 or -12.12% compared to the previous year.
Employees
29
Change (1Y)
-4
Growth (1Y)
-12.12%
Revenue / Employee
n/a
Profits / Employee
-$1,446,483
Market Cap
35.91M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | -4 | -12.12% |
Dec 31, 2022 | 33 | 10 | 43.48% |
Dec 31, 2021 | 23 | 15 | 187.50% |
Dec 31, 2020 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ELEV News
- 5 weeks ago - Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones - PRNewsWire
- 2 months ago - Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PRNewsWire
- 2 months ago - Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - PRNewsWire
- 2 months ago - Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PRNewsWire
- 3 months ago - Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 3 months ago - Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PRNewsWire
- 4 months ago - Empery Asset Management's Strategic Acquisition in Elevation Oncology - GuruFocus
- 5 months ago - Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - PRNewsWire